Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436), a renowned traditional Chinese medicine (TCM) company in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its PZH2113. This is an in-house developed Category 1 chemical drug intended for the treatment of recurrent/refractory non-Hodgkin’s lymphoma, primarily diffuse large B-cell lymphoma.
After preliminary pharmaceutical, pharmacological, toxicological, and non-clinical safety evaluation studies, PZH2113 has demonstrated good safety, drug efficacy, and clinical development value.- Flcube.com
